IL28B (IFNL3) rs12979860 predicts response to interferon-α2a plus ribavirin in Pakistani adults with chronic hepatitis C
A longitudinal cohort study
DOI:
https://doi.org/10.59736/IJP.23.04.1014Keywords:
Genotype 3, Hepatitis C, IL28B, rs12979860, Interferon, Ribavirin, Sustained Virologic ResponseAbstract
Background: Chronic hepatitis C virus (HCV) remains highly prevalent in Pakistan, with genotype 3 predominance. Before direct-acting antivirals (DAAs), interferon-α (IFN) plus ribavirin (RBV) yielded variable sustained virologic response (SVR). Host variants near IL28B (IFNL3), particularly rs12979860, have been linked to IFN responsiveness and spontaneous clearance. This study evaluates whether IL28B rs12979860 predicts SVR to IFN-α2a/RBV in Pakistani adults and to describe baseline viral-load strata and circulating genotypes.
Methods: We conducted a longitudinal cohort in Khushal Medical Center (KMC) Peshawar (N=165). Adult’s anti-HCV–positive by third-generation ELISA started IFN-α2a thrice weekly plus weight-based RBV for 24–48 weeks. Baseline demographics, HCV RNA categories, and viral genotypes were recorded; IL28B rs12979860 was genotyped from whole blood. Virologic endpoints were Rapid viral response (RVR) (week 4), Early virological response (EVR) (week 12), and SVR (undetectable HCV RNA 24 weeks post-therapy). Associations were summarized as odds ratios (OR) with 95% CIs.
Results: Overall SVR was 51.5% (85/165). Baseline RNA was <600,000 IU/mL in 81.8%, 600,000–800,000 in 2.4%, and >800,000 in 15.7%; all SVR events occurred in the <600,000 IU/mL group. Genotypes were dominated by 3a (45%) and 3b (19%) with smaller contributions from 2a (13%), 1a (6%), 2b (5%); 4a/5a/6a were rare; ~10% were untypeable. rs12979860 distributions differed by outcome: responders (n=84) CC 45, CT 32, TT 7; non-responders (n=80) CC 21, CT 26, TT 33. CC vs TT: OR 10.10 (95% CI 3.84–26.55); CC vs CT+TT: OR 3.24 (95% CI 1.68–6.25). EVR tracked positively with SVR.
Conclusions: In a genotype-3–predominant Pakistani cohort, rs12979860-CC strongly predicted SVR to IFN-α2a/RBV (CC>CT>TT). These data provide population-specific pharmacogenomic evidence and a historical benchmark for Pakistan.
References
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45.e7.
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.
Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: a systematic review. Virol J. 2011; 8:433.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40.
Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol. 2016;22(4):1684–1700.
Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein/LDL analyzed in iodixanol density gradients. J Virol. 2006;80(5):2418–28.
Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba KI, Orito E, et al. New hepatitis C virus genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201–7.
R Core Team. R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. 2021.
Jafri W, Subhan A. Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. Trop Gastroenterol. 2008;29(4):194–201.
Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004;40(6):1260–65.
Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, et al. Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One. 2014;9(9): e107592.
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38(3):645–52.
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43(3):425–33.
Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357(2):124–34.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alfa-2a/ribavirin therapy. Hepatology. 2006;43(5):954–60.
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peginterferon alfa-2b and ribavirin. Aliment Pharmacol Ther. 2010;31(12):1346–53.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.
Younas S, Maqsood Q, Sumrin A, Khan MU, Hussain N. Efficacy of direct-acting antivirals in treatment-naive chronic HCV patients and in those previously treated with interferon and ribavirin. Pakistan J. Zool. 2024.1-8, DOI: https://dx.doi.org/10.17582/journal.pjz/2023081813582
Majid A, Khan S, Siraj S, Haleem S, Ul Haq N, Ullah R, et al. Emergence of resistance against direct-acting antivirals in chronic HCV patients: a real-world study. Saudi J Biol Sci. 2022;29(4):2613–9.
Martinelli D, Fortunato F, Simsek G, Prato R. Epidemiology and prevention of viral hepatitis B and C. Practical Management of Chronic Viral Hepatitis. 2013 May 29.
Published
Issue
Section
License
Copyright (c) 2025 Naimat Ullah Khan, Syed Hasnain Ali Shah, Shandana Altaf, Summayya Anwar, Tariq Mahfooz Khawaja, Imran Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
